Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16657407 | 0.86 | RAB9A (0.41) | KMT2AKDM4EMTNR1AMTNR1BALDH1A1 | |
| SCHEMBL20552536 | 0.79 | L3MBTL1 (0.55) | KMT2AKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL9941197 | 0.75 | BACE1 (0.42) | KMT2AKDM4EBACE1 | |
| SCHEMBL25767043 | 0.69 | ACSS2 (0.46) | KDM4EMTNR1AMTNR1BALDH1A1EHMT2 | |
| SCHEMBL9974600 | 0.68 | CNR2 (0.43) | KMT2AKDM4EALDH1A1MAPTL3MBTL1 | |
| SCHEMBL9979854 | 0.68 | BACE1 (0.54) | KMT2AKDM4EALDH1A1MAPTBACE1 | |
| SCHEMBL3752568 | 0.68 | KDM4E (0.55) | KMT2AKDM4EMTNR1AMTNR1BALDH1A1 | |
| SCHEMBL16254657 | 0.67 | NOD1 (0.46) | KMT2AKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL9974837 | 0.67 | ALDH1A1 (0.46) | KDM4EALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL16657416 | 0.66 | SMN1; SMN2 (0.39) | KMT2AKDM4EALDH1A1MAPTBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251377-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-09-01 | — | — | US | claimed |
| US-9896459-B2 | Azaindoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-20 | — | — | US | disclosed |
| EP-2909195-B1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-06-14 | — | — | EP | disclosed |
| EP-2909195-B1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-06-14 | — | — | EP | disclosed |
| US-9617289-B2 | RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-11 | — | — | US | disclosed |
| US-9617289-B2 | RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-11 | — | — | US | disclosed |
| US-9617289-B2 | RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-11 | — | — | US | disclosed |
| EP-2651936-B1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-02-22 | — | — | EP | disclosed |
| US-20160251377-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-09-01 | — | — | US | disclosed |
| US-20160251377-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-09-01 | — | — | US | disclosed |
| US-20150231119-A1 | Azaindoles As Respiratory Syncytial Virus Antiviral Agents | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-20 | — | — | US | disclosed |
| US-20150231119-A1 | Azaindoles As Respiratory Syncytial Virus Antiviral Agents | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-20 | — | — | US | disclosed |
| US-20150158862-A1 | 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (US) | 2015-06-11 | — | — | US | disclosed |
| US-9051317-B2 | Azaindoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-09 | — | — | US | disclosed |
| US-9051317-B2 | Azaindoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-09 | — | — | US | disclosed |
| WO-2014060411-A1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN R&D IRELAND (IE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060411-A1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN R&D IRELAND (IE) | 2014-04-24 | — | — | WO | disclosed |
| US-20130267556-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2013-10-10 | — | — | US | disclosed |
| US-20130267556-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080450-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158862-A1 | 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, HELZ, SARS1 | KMT2A 2944/4885KDM4E 2658/4885MTNR1A 985/4885 |
| US-20150231119-A1 | Azaindoles As Respiratory Syncytial Virus Antiviral Agents | AZI2, CCNI, ZC3HAV1 | KMT2A 1619/4885KDM4E 1448/4885MTNR1A 366/4885 |
| US-20160251377-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | AZI2, CCNI, ZC3HAV1 | KMT2A 1619/4885KDM4E 1448/4885MTNR1A 366/4885 |
| US-20130267556-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | AZI2, CCNI, ZC3HAV1 | KMT2A 1619/4885KDM4E 1448/4885MTNR1A 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.